FOR IMMEDIATE RELEASE

October 18, 2005.

Eidogen-Sertanty Announces DirectDesign Discovery Collaboration with KAI Pharmaceuticals.

San Diego, CA (October 18, 2005) – Eidogen-Sertanty, Inc., a San Diego-based computational drug discovery solutions provider, today announced that they have engaged in a collaborative service project with KAI Pharmaceuticals, a South San Francisco-based drug discovery company focused on the development of Protein Kinase C (PKC) modulators.

Under the terms of the service arrangement, Eidogen-Sertanty will utilize the Target Informatics Platform (TIP™) and EVE Comparative Visualization software within its DirectDesign™ Discovery Service to perform extensive structural characterization and comparative binding site analysis for PKC regulatory domains. The collaborative project will allow KAI to further enhance its unique insights into PKC isozyme selectivity, as well as to advance KAI's strategies for pharmacophore-based design of modulators of PKC activity.

KAI Pharmaceuticals is developing specific and selective modulators of PKCs for a variety of human diseases, with its lead product in clinical development for acute cardiovascular diseases.

"The unique attributes of Eidogen-Sertanty’s EVE Visualization Software provide powerful capabilities for protein comparison and pharmacophore mapping. We view our relationship with Eidogen-Sertanty as a potentially important part of our drug design strategy", said Derek Maclean, Senior Scientist at KAI Pharmaceuticals.

“We are very pleased to work with KAI on this project. In addition to our software and database business, our DirectDesign Discovery Service offering allows product-focused companies such as KAI to gain significant value from the proteome-wide comparative structural informatics capabilities of our TIP platform,” said Steve Muskal, CEO of Eidogen-Sertanty.

About KAI Pharmaceuticals
KAI Pharmaceuticals is a biology-based, product-driven, drug discovery and development company leveraging protein kinase C (PKC) signaling to generate a portfolio of clinical and preclinical drug candidates for the treatment of acute cardiovascular and other important human diseases. The company is applying its core expertise in the biology of translocation of PKC isozymes to develop highly specific activators and inhibitors of PKC. KAI has received ‘Fast Track’ designation for its lead drug candidate, KAI-9803, currently being investigated in a Phase I/II clinical trial as a treatment to prevent ischemia induced reperfusion injury in acute myocardial infarction. KAI Pharmaceuticals is based in South San Francisco, California, and can be found online at www.KAIpharma.com.

About Eidogen-Sertanty, Inc.
Eidogen-Sertanty, formed in March 2005 from the merger of Eidogen and Sertanty, is a privately held company providing pioneering knowledge-driven discovery solutions to biotechnology and pharmaceutical organizations. Eidogen-Sertanty’s unique and powerful suite of software, databases, and drug discovery services enable customers and collaborators to apply a knowledge-driven discovery approach to a variety of workflows and processes, including target selection and prioritization, library building and compound prioritization, and lead design and optimization. To find out more about Eidogen-Sertanty and their products and services please visit www.eidogen-sertanty.com

CONTACTS:

Contact Information: Janet Roberts, Alan Herman & Assoc. 949-443-1695 janet@ahamar.com